Add like
Add dislike
Add to saved papers

Conformal 3D planned radiotherapy for pelvic lymphoceles following surgery for urological cancer: A case study.

The aim of the present study was to evaluate the outcome and toxicity of 3D conformal radiotherapy (RT) for persistent lymphoceles following surgery for urological cancer. A total of 6 patients with bladder (n=1) and prostate cancer (n=5), with persistent lymphoceles following surgery for a primary tumor were treated with total doses of 10-12 Gy (1 Gy single dose) after computed tomography (CT) based 3D planning in order to suspend secretion. No acute or chronic toxicities were observed. In 5 patients, secretion of lymph fluid resolved after RT and in 1 patient RT had no effect. After a mean follow-up of 21 months (range, 5-47 months), no patient suffered from any symptoms concerning his former lymphoceles. This is the first analysis, to the best of our knowledge, to evaluate a homogenous patient collective of urological cancer patients with persistent lymphoceles after surgery for the initial tumor. RT to lymphoceles in urological cancer patient is effective, very well-tolerated and should be offered to patients with persistent secretion following drainage.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app